Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Summary

This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with treatment (advanced). Systemic mastocytosis is a disease in which too many mast cells (a type of immune system cell) are found throughout the body. Mast cells give off chemicals such as histamine that can cause flushing (a hot, red face), itching, abdominal cramps, muscle pain, nausea, vomiting, diarrhea, low blood pressure, and shock. Ibrutinib may stop the growth of mast cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2015-03

Primary completion

2016-11-04

Completion

2017-06-14

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

Indications